Vancomycin-associated nephrotoxicity in the critically ill: A retrospective multivariate regression analysis

Critical Care Medicine

Volumn 42, Issue 12, 2014, Pages 2527-2536

  Hanrahan, Timothy P ^a,b   Harlow, Georgina ^c   Hutchinson, James ^c   Dulhunty, Joel M ^b   Lipman, Jeffrey ^a,b   Whitehouse, Tony ^c   Roberts, Jason A ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^c UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Acute kidney injury; Glycopeptide; Infection; Intensive care unit; Sepsis; Vancomycin

Indexed keywords

VANCOMYCIN; VASOACTIVE AGENT; ANTIINFECTIVE AGENT; CREATININE;

ACUTE KIDNEY FAILURE; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CONTINUOUS INFUSION; CRITICALLY ILL PATIENT; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG INTERMITTENT THERAPY; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM PLASMA CONCENTRATION; MORTALITY; NEPHROTOXICITY; OBSERVATIONAL STUDY; PREDICTOR VARIABLE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION; BLOOD; CHEMICALLY INDUCED; CRITICAL ILLNESS; DOSE RESPONSE; DRUG ADMINISTRATION; MIDDLE AGED; ORGAN DYSFUNCTION SCORE; PREVALENCE; REGRESSION ANALYSIS;

ACUTE KIDNEY INJURY; AGED; ANTI-BACTERIAL AGENTS; CREATININE; CRITICAL ILLNESS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; ORGAN DYSFUNCTION SCORES; PREVALENCE; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; VANCOMYCIN;

EID: 84922526908     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0000000000000514     Document Type: Article

References (26)

1. Vincent JL, Rello J, Marshall J, et al; EPIC II Group of Investigators: International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009;302:2323-2329
2. Vincent JL, Sakr Y, Sprung CL, et al; Sepsis Occurrence in Acutely Ill Patients Investigators: Sepsis in European intensive care units: Results of the SOAP study. Crit Care Med 2006;34:344-353
3. Hanberger H, Walther S, Leone M, et al; EPIC II Group of Investigators: Increased mortality associated with methicillin-resistant Staphylococcus aureus (MRSA) infection in the intensive care unit: Results from the EPIC II study. Int J Antimicrob Agents 2011;38:331-335
4. Klevens RM, Morrison MA, Nadle J, et al; Active Bacterial Core surveillance (ABCs) MRSA Investigators: Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007;298:1763-1771
5. van Duijn PJ, Dautzenberg MJ, Oostdijk EA: Recent trends in antibiotic resistance in European ICUs. Curr Opin Crit Care 2011;17:658-665
6. Howden BP, Ward PB, Charles PG, et al: Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 2004;38:521-528
7. Sakoulas G, Gold HS, Cohen RA, et al: Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia. J Antimicrob Chemother 2006;57:699-704
8. Wong-Beringer A, Joo J, Tse E, et al: Vancomycin-associated nephrotoxicity: A critical appraisal of risk with high-dose therapy. Int J Antimicrob Agents 2011;37:95-101
9. American Thoracic Society, Infectious Diseases Society of America: Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416
10. Rybak M, Lomaestro B, Rotschafer JC, et al: Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009;66:82-98
11. Pritchard L, Baker C, Leggett J, et al: Increasing vancomycin serum trough concentrations and incidence of nephrotoxicity. Am J Med 2010;123:1143-1149
12. Lodise TP, Lomaestro B, Graves J, et al: Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 2008;52:1330-1336
13. Lipman J: Is the end-game penetration (of the airway) ? Crit Care Med 2005;33:1654-1655
14. Covic A, Goldsmith DJ, Segall L, et al: Rifampicin-induced acute renal failure: A series of 60 patients. Nephrol Dial Transplant 1998;13:924-929
15. Rosati S, Cherubini C, Iacomi F, et al: Acute rifampicin-associated interstitial tubulopathy in a patient with pulmonary tuberculosis: A case report. J Med Case Rep 2013;7:106
16. Vincent JL, Moreno R, Takala J, et al: The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996;22:707-710
17. Levey AS, Bosch JP, Lewis JB, et al: A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-470
18. Bellomo R, Ronco C, Kellum JA, et al; Acute Dialysis Quality Initiative Workgroup: Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: The Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004;8:R204-R212
19. Jeffres MN, Isakow W, Doherty JA, et al: A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Clin Ther 2007;29:1107-1115
20. Hidayat LK, Hsu DI, Quist R, et al: High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: Efficacy and toxicity. Arch Intern Med 2006;166:2138-2144
21. Cataldo MA, Tacconelli E, Grilli E, et al: Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections: Systematic review and meta-analysis. J Antimicrob Chemother 2012;67:17-24
22. Kitzis MD, Goldstein FW: Monitoring of vancomycin serum levels for the treatment of staphylococcal infections. Clin Microbiol Infect 2006;12:92-95
23. Roberts JA, Lipman J, Blot S, et al: Better outcomes through continuous infusion of time-dependent antibiotics to critically ill patients? Curr Opin Crit Care 2008;14:390-396
24. Roberts JA, Taccone FS, Udy AA, et al.: Vancomycin dosing in critically ill patients: Robust methods for improved continuous-infusion regimens. Antimicrob Agents Chemother 2011;55:2704-2709
25. Wysocki M, Delatour F, Faurisson F, et al: Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: Prospective multicenter randomized study. Antimicrob Agents Chemother 2001;45:2460-2467
26. Vuagnat A, Stern R, Lotthe A, et al: High dose vancomycin for osteomyelitis: Continuous vs. intermittent infusion. J Clin Pharm Ther 2004;29:351-357